Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.ORCID-id: 0000-0001-5384-8038
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.ORCID-id: 0000-0003-2018-8592
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi. Umeå universitet, Medicinska fakulteten, Molekylär Infektionsmedicin, Sverige (MIMS). Umeå universitet, Medicinska fakulteten, Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM).
Visa övriga samt affilieringar
2023 (Engelska)Ingår i: Frontiers in Immunology, E-ISSN 1664-3224, Vol. 14, artikel-id 1219560Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Peripheral B cell depletion via anti-CD20 treatment is a highly effective disease-modifying treatment for reducing new relapses in multiple sclerosis (MS) patients. A drawback of rituximab (RTX) and other anti-CD20 antibodies is a poor immune response to vaccination. While this can be mitigated by treatment interruption of at least six months prior to vaccination, the timing to resume treatment while maintaining subsequent vaccine responses remains undetermined. Here, we characterized SARS-CoV-2 S-directed antibody and B cell responses throughout three BNT162b2 mRNA vaccine doses in RTX-treated MS patients, with the first two doses given during treatment interruption. We examined B-cell mediated immune responses in blood samples from patients with RTX-treated MS throughout three BNT162b2 vaccine doses, compared to an age- and sex-matched healthy control group. The first vaccine dose was given 1.3 years (median) after the last RTX infusion, the second dose one month after the first, and the third dose four weeks after treatment re-initiation. We analyzed SARS-CoV-2 S-directed antibody levels using enzyme-linked immunosorbent assay (ELISA), and the neutralization capacity of patient serum against SARS-CoV-2 S-pseudotyped lentivirus using luciferase reporter assay. In addition, we assessed switched memory (CD19+CD20+CD27+IgD-), unswitched memory (CD19+CD20+CD27+IgD+), naïve (CD19+CD20+CD27-IgD+), and double negative (DN, CD19+CD20+CD27-IgD-) B cell frequencies, as well as their SARS-CoV-2 S-specific (CoV+) and Decay Accelerating Factor-negative (DAF-) subpopulations, using flow cytometry. After two vaccine doses, S-binding antibody levels and neutralization capacity in SARS-CoV-2-naïve MS patients were comparable to vaccinated healthy controls, albeit with greater variation. Higher antibody response levels and CoV+-DN B cell frequencies after the second vaccine dose were predictive of a boost effect after the third dose, even after re-initiation of rituximab treatment. MS patients also exhibited lower frequencies of DAF- memory B cells, a suggested proxy for germinal centre activity, than control individuals. S-binding antibody levels in RTX-treated MS patients after two vaccine doses could help determine which individuals would need to move up their next vaccine booster dose or postpone their next RTX infusion. Our findings also offer first indications on the potential importance of antigenic stimulation of DN B cells and long-term impairment of germinal centre activity in rituximab-treated MS patients.

Ort, förlag, år, upplaga, sidor
Frontiers Media S.A., 2023. Vol. 14, artikel-id 1219560
Nyckelord [en]
B cell immunology, COVID-19, multiple sclerosis, rituximab, vaccination
Nationell ämneskategori
Infektionsmedicin Immunologi inom det medicinska området
Identifikatorer
URN: urn:nbn:se:umu:diva-212992DOI: 10.3389/fimmu.2023.1219560PubMedID: 37575257Scopus ID: 2-s2.0-85167514064OAI: oai:DiVA.org:umu-212992DiVA, id: diva2:1789364
Forskningsfinansiär
Region Västerbotten, RV-969133Vetenskapsrådet, 2020-0625Vetenskapsrådet, 2021-04665Knut och Alice Wallenbergs Stiftelse, VA-2021-0018Knut och Alice Wallenbergs Stiftelse, VA-2022-0008Science for Life Laboratory, SciLifeLabTillgänglig från: 2023-08-18 Skapad: 2023-08-18 Senast uppdaterad: 2024-01-17Bibliografiskt granskad

Open Access i DiVA

fulltext(2175 kB)66 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 2175 kBChecksumma SHA-512
35c8a5834d73963dcf5c68c38d7e834d259ccd0ab5e46371d5e92edc2389512c9dccd73b3c5c06f99a58f8182c5f902f0b586b72dbc0093d58a4159a3c102c09
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Gröning, RemigiusDernstedt, AndyAhlm, ClasNormark, JohanSundström, PeterForsell, Mattias N. E.

Sök vidare i DiVA

Av författaren/redaktören
Gröning, RemigiusDernstedt, AndyAhlm, ClasNormark, JohanSundström, PeterForsell, Mattias N. E.
Av organisationen
Institutionen för klinisk mikrobiologiMolekylär Infektionsmedicin, Sverige (MIMS)Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM)Neurovetenskaper
I samma tidskrift
Frontiers in Immunology
InfektionsmedicinImmunologi inom det medicinska området

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 71 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 294 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf